Trial shows effectiveness of hepatitis C drug telaprevir

04/7/2010 | Bloomberg Businessweek

About 50% of hepatitis C patients who did not respond to the standard treatment of peginterferon alpha plus ribavirin in the first round of therapy were virus-free six months after being treated with the two drugs plus telaprevir in the second round, according to a study. Only 14% of those who had the same two-drug treatment in the second round were virus-free after six months. Telaprevir presents an additional option for hepatitis C patients who do not respond to standard treatment, the lead author said.

View Full Article in:

Bloomberg Businessweek

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
NGS Provider Enrollment Rep
National Government Services - WellPoint
Harrisburg, PA
Program Manager II
Tufts Health Plan/Network Health
Medford, MA
Director, Medicare Advantage/Medicare Part D Focus
Avalere Health
Washington, DC
Chief, Product Review Branch
FDA/Center for Biologics Evaluation and Research
Silver Spring, MD
Director of Clinical Research
Regenesis Biomedical, Inc.
Scottsdale, AZ